Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

PURPOSE: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. EXPERIMENTAL DESIGN: In vitro and in vivo models, and a phase I stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Di Cosimo, Serena, Sathyanarayanan, Sriram, Bendell, Johanna C., Cervantes, Andrés, Stein, Mark N., Braña, Irene, Roda, Desamparados, Haines, Brian B., Zhang, Theresa, Winter, Christopher G., Jha, Sharda, Xu, Youyuan, Frazier, Jason, Klinghoffer, Richard A., Leighton-Swayze, Ann, Song, Yang, Ebbinghaus, Scot, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705197/
https://ncbi.nlm.nih.gov/pubmed/25320355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0940
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados